<unk>  is a histone deacetylase inhibitor that is FDA approved for the treatment of patients with multiple myeloma (in combination with bortezomib and dexamethasone) who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include diarrhea, fatigue, nausea, peripheral edema, decreased appetite, pyrexia, and vomiting (≥20%).
Panobinostat
Olaparib
Vorinostat
Febuxostat
Dabrafenib mesylate
Cetuximab
Raltitrexed
Ribociclib